Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned an average recommendation of "Buy" from the twelve ratings firms that are covering the company, MarketBeat.com reports. One...